Known targets — ChEMBL curated mechanism
ATP1A1ATP1A2ATP1A3ATP1A4ATP1B1ATP1B2ATP1B3ATP2A2FXYD2
The experimentally established mechanism targets of Istaroxime. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 known ✓ | P05023 | 10/20 | 0.89 |
| ▸ | ATP1B1 known ✓ | P05026 | 10/20 | 0.89 |
| ▸ | ATP1A3 known ✓ | P13637 | 10/20 | 0.89 |
| ▸ | ATP1B2 known ✓ | P14415 | 10/20 | 0.89 |
| ▸ | ATP1A2 known ✓ | P50993 | 10/20 | 0.89 |
| ▸ | ATP1B3 known ✓ | P54709 | 10/20 | 0.89 |
| ▸ | FXYD2 known ✓ | P54710 | 10/20 | 0.89 |
| ▸ | ATP1A4 known ✓ | Q13733 | 10/20 | 0.89 |
| ▸ | ATP12A | P54707 | 4/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.60 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Istaroxime SCHEMBL7285898 | 1.00 | ATP12A (1.00) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL8452195 | 1.00 | ATP12A (1.00) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL1427268 | 1.00 | ATP12A (1.00) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL7298591 | 1.00 | ATP12A (1.00) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL8450412 | 1.00 | ATP12A (1.00) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL23760714 | 1.00 | ATP12A (1.00) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL5053480 | 1.00 | ATP12A (1.00) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL7285904 | 1.00 | ATP12A (1.00) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL22116205 | 1.00 | ATP12A (1.00) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 | |
| Istaroxime SCHEMBL29375996 | 1.00 | ATP12A (1.00) | ATP12AATP1A1ATP1B1ATP1A3ATP1B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723757-B2 | 6-substituted estradiol derivatives and methods of use | ENDECE LLC (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190135853-A1 | 6-Substituted Estradiol Derivatives and Methods of Use | ENDECE LLC | 2019-05-09 | — | — | US | disclosed |
| US-10174070-B2 | 6-substituted estradiol derivatives and methods of use | ENDECE LLC (US) | 2019-01-08 | — | — | US | disclosed |
| EP-2300016-B1 | 6-SUBSTITUTED ESTRADIOL DERIVATIVES AND METHODS OF USE | ENDECE LLC (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-2099460-B1 | 6-ALKOXYALKYL ESTRADIOL DERIVATIVES AND METHODS OF USE | ENDECE LLC (US) | 2016-09-07 | — | — | EP | disclosed |
| EP-2507253-B1 | 6-SUBSTITUTED ESTRADIOL DERIVATIVES AND METHODS OF USE | ENDECE LLC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-8629130-B2 | 6-substituted estradiol derivatives and methods of use | ENDECE, LLC (US) | 2014-01-14 | — | — | US | disclosed |
| US-20120270817-A1 | 6-Substituted Estradiol Derivatives and Methods of Use | YARGER JAMES G (US) | 2012-10-25 | — | — | US | disclosed |
| US-8168621-B2 | 6-substituted estradiol derivatives and methods of use | ENDECE, LLC (US) | 2012-05-01 | — | — | US | disclosed |
| EP-2300016-A1 | 6-SUBSTITUTED ESTRADIOL DERIVATIVES AND METHODS OF USE | Endece, LLC (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-1156058-A3 | Process for the preparation of (E,Z) 3-(2-aminoethoxyimino)-androstane-6,17-dione and its analogues | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2005-06-08 | — | — | EP | disclosed |
| US-6384250-B2 | HYDROXYLATION; REDUCTION; OXIDATION; OXIMINATION | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-05-07 | — | — | US | disclosed |
| US-6384250-B2 | HYDROXYLATION; REDUCTION; OXIDATION; OXIMINATION | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-05-07 | — | — | US | disclosed |
| US-6384250-B2 | HYDROXYLATION; REDUCTION; OXIDATION; OXIMINATION | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-05-07 | — | — | US | disclosed |
| US-20010056182-A1 | Process for the preparation of (E,Z) 3-(2-aminoethoxyimino)-androstane-6,17-dione and its analogues | GOBBINI MAURO (IT) | 2001-12-27 | — | — | US | disclosed |
| US-20010056182-A1 | Process for the preparation of (E,Z) 3-(2-aminoethoxyimino)-androstane-6,17-dione and its analogues | GOBBINI MAURO (IT) | 2001-12-27 | — | — | US | disclosed |
| US-20010056182-A1 | Process for the preparation of (E,Z) 3-(2-aminoethoxyimino)-androstane-6,17-dione and its analogues | GOBBINI MAURO (IT) | 2001-12-27 | — | — | US | disclosed |
| EP-1156058-A2 | Process for the preparation of (E,Z) 3-(2-aminoethoxyimino)-androstane-6,17-dione and its analogues | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2001-11-21 | — | — | EP | disclosed |
| EP-1156058-A2 | Process for the preparation of (E,Z) 3-(2-aminoethoxyimino)-androstane-6,17-dione and its analogues | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2001-11-21 | — | — | EP | disclosed |
| EP-1156058-A2 | Process for the preparation of (E,Z) 3-(2-aminoethoxyimino)-androstane-6,17-dione and its analogues | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2001-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723757-B2 | 6-substituted estradiol derivatives and methods of use | SHBG, HSD17B11, CYP19A1 | ATP1A1 2191/4885ATP1B1 1893/4885ATP1A3 1188/4885 |
| US-20190135853-A1 | 6-Substituted Estradiol Derivatives and Methods of Use | SHBG, HSD17B11, CYP19A1 | ATP1A1 2191/4885ATP1B1 1893/4885ATP1A3 1188/4885 |
| US-10174070-B2 | 6-substituted estradiol derivatives and methods of use | NR3C2, SHBG, NR5A1 | ATP1A1 2035/4885ATP1B1 1902/4885ATP1A3 891/4885 |
| US-20010056182-A1 | Process for the preparation of (E,Z) 3-(2-aminoethoxyimino)-androstane-6,17-dione and its analogues | CYP17A1, CYP19A1, HSD17B11 | ATP1A1 3403/4885ATP1B1 2185/4885ATP1A3 3925/4885 |
| US-20120270817-A1 | 6-Substituted Estradiol Derivatives and Methods of Use | ESRRA, ESR2, ESRRB | ATP1A1 3347/4885ATP1B1 2891/4885ATP1A3 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.